Welcome to our dedicated page for Zentek news (Ticker: ZTEK), a resource for investors and traders seeking the latest updates and insights on Zentek stock.
Zentek Ltd. (ZTEK) generates news across several advanced technology domains, reflecting its role as an intellectual property development and commercialization company. Its disclosures highlight activity in graphene-based coatings, critical mineral development, aptamer-based healthcare technologies and fire-retardant materials, giving investors and observers multiple streams of company-specific updates.
A major news theme is Zentek’s work through its wholly owned subsidiary Albany Graphite Corp. on the Albany Graphite Project in Ontario. Recent releases describe ultra-high purity Albany graphite reaching five-nines carbon purity with an Equivalent Boron Concentration below thresholds generally referenced for nuclear applications, as well as additional nuclear suitability testing and independent verification using near-net-shaped graphite bricks. Separate announcements cover lithium-ion battery suitability testing, where spheroidized Albany graphite has shown near-theoretical anode performance under industry-standard conditions.
Another recurring topic is Zentek’s ZenGUARD™ platform for surgical masks and HVAC air filters, including corporate updates on testing under the Government of Canada’s Innovative Solutions Canada program and efforts to advance ZenGUARD™ Enhanced Air Filters in Canada and international markets. News items also address the company’s development of a Graphite Gel-Based Fire-Retardant product and an exclusive licensing arrangement with Altek Advanced Materials Inc. for commercialization in the United States.
Healthcare-focused news includes progress on multivalent aptamer countermeasures against influenza through Triera Biosciences and McMaster University, supported by a federal testing contract. Corporate governance and capital markets developments, such as CEO transitions, board appointments, annual meeting voting results and tax reassessment matters, are reported through regular press releases and associated Form 6-K filings. Readers following ZTEK news can expect updates on technology milestones, regulatory and testing programs, strategic partnerships and key corporate decisions.
Zentek (NASDAQ:ZTEK) announced that its subsidiary, Albany Graphite (AGC), has achieved ultra-high purity of 99.9991% from its Albany graphite deposit using a pilot-scale fluidized bed reactor (FBR). The purification was performed directly on a ~950g sample of Albany flotation concentrate with 85% Total Graphitic Carbon, eliminating the need for intermediate hydrometallurgical steps.
The process yielded extremely low total impurities of 9 ppm against the industry standard maximum of 500 ppm for advanced battery applications. The company will continue testing the material for lithium-ion battery anode components and nuclear industry applications. Notably, this purification was achieved without using chlorine or halogen gases, which are commonly required for achieving five-nines purity levels.
The Albany Graphite Project, located near Hearst, Ontario, consists of 521 mining claims and is situated within 30 km of the Trans-Canada Highway, with access to established infrastructure including roads, rail, power, and natural gas.
Zentek (NASDAQ:ZTEK) has signed a Memorandum of Understanding with Al-Ramez International Group through Saudi Excellence Holding Company to establish a strategic partnership in Saudi Arabia and the MENA region. The collaboration aims to develop a graphene production facility focusing on ZenGUARD™ technologies and create a commercialization hub for Zentek's technologies.
The partnership encompasses multiple objectives, including advancing Triera Biosciences' aptamer technology, developing the Albany Graphite Deposit, and establishing research facilities in conjunction with Saudi universities. Additionally, Zentek has been accepted into the World Trade Centre Toronto's Trade Accelerator Program to support its international expansion efforts.
Zentek has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received notification from Nasdaq on December 3, 2024, confirming that it has met the listing rule 5550(a)(2), which requires securities to maintain a minimum bid price of US$1.00 per share. Zentek's common stock has traded above the US$1.00 threshold for 11 consecutive business days, satisfying the requirement.
Zentek (NASDAQ:ZTEK) announces plans to add ZenGUARD™ Enhanced Air Filters under its existing medical device establishment licence (MDEL). Independent testing showed the filters achieve ~66% viral filtration efficiency enhancement compared to untreated filters, maintaining ~67% VFE over 6 months with minimal pressure drop changes. A ParticleOne study demonstrated the product's effectiveness in reducing viral pathogens and potential cost savings from reduced absenteeism. The company will need additional testing and documentation to qualify the filters as a medical device under MDEL and ISO 13485:2016 compliance. Additionally, Nick Hansford, VP of Strategy and Product Development, has departed the company.
Zentek and its subsidiary Triera Biosciences have secured a $1.1 million contract from the Government of Canada to test their multivalent aptamer technology for rapid drug discovery targeting highly pathogenic avian influenza (HPAI) A(H5N1). The project involves collaboration with Health Emergency Readiness Canada (HERC) and Defence Research and Development Canada (DRDC). Triera must develop a lead candidate within six months, which will be tested for therapeutic and prophylactic efficacy at McMaster University. The company has previously demonstrated success with this platform by developing a universal therapeutic effective against all SARS-CoV-2 variants.
Zentek (NASDAQ:ZTEK) has withdrawn its submission to Health Canada's Pest Management Regulatory Agency (PMRA) for ZenGUARD™ Enhanced Air Filters. Based on PMRA feedback and analysis of the Canadian regulatory environment, the company will pursue alternative, more cost-effective and timely pathways to bring the product to market in Canada. The company had been evaluating these alternative options while awaiting PMRA assessment. ZenGUARD™ filters are designed to control infectious aerosols without significantly increasing energy consumption and emissions in buildings.
Zentek (NASDAQ:ZTEK)(TSXV:ZEN) has provided an update on the commercialization of its ZenGUARD™ Antimicrobial Surgical Masks. Following a Canada-wide sampling program for dental professionals through Henry Schein Inc., the company is experiencing increased demand for its product. Zentek is exploring opportunities in the beauty space and international healthcare markets. The company has applied to the FDA for authorization to sell ZenGUARD™ Surgical Masks in the United States and is currently evaluating additional information requests from the FDA.
CEO Greg Fenton highlighted that ZenGUARD™ masks not only provide better protection against infectious agents but also eliminate 99.9% of bacteria that can cause acne when wearing masks for extended periods. This unique value proposition is expected to drive demand in the dental market and potentially in the beauty industry.
Zentek (NASDAQ: ZTEK) (TSXV: ZEN) held its annual and special meeting of shareholders on September 26, 2024. Shareholders voted in favor of all resolutions presented. The meeting included the election of directors, with all nominees listed in the Management Information Circular being elected. Voting results for directors ranged from 81.258% to 98.899% in favor.
Shareholders also approved the appointment of BDO Canada LLP as the Company's auditors with 99.275% of votes in favor. Additionally, the Company's omnibus long-term incentive plan was approved and confirmed with 82.077% of votes in favor and 17.923% against.
The Management Information Circular, dated August 19, 2024, containing details of all resolutions, is available on the Company's SEDAR+ profile.
Zentek (NASDAQ: ZTEK) (TSXV: ZEN) has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's shares have traded below $1.00 for 31 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Zentek has until March 10, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day grace period. Failure to meet requirements could result in delisting, though Zentek can appeal such a decision. The company's management is actively monitoring the situation and considering options to address the deficiency.
Zentek (Nasdaq:ZTEK, TSXV:ZEN) has announced plans for a normal course issuer bid, subject to regulatory approval. The company aims to repurchase up to 5,084,319 common shares, representing approximately 5% of its outstanding shares, over a one-year period from August 16, 2024, to August 15, 2025. Zentek can purchase up to 2,033,727 shares (2% of outstanding shares) in any 30-day period during the bid.
Management believes this strategy will increase long-term shareholder value, as the current market price may not fully reflect the company's business value and future prospects. Purchases will be made through the TSX Venture Exchange at market prices, with Integral Wealth Securities appointed as the broker for these transactions.